Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550783 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL551124 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL551031 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL2699309 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL550782 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL549526 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL2699313 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL2699862 | 1.00 | HSD11B1 (0.36) | HSD11B1RIPK1CHRM4NPY5RBMPR1A | |
| SCHEMBL5630802 | 0.90 | HSD11B1 (0.37) | HSD11B1RIPK1CHRM4NPY5ROPRK1 | |
| SCHEMBL5630452 | 0.90 | HSD11B1 (0.37) | HSD11B1RIPK1CHRM4NPY5ROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885RIPK1 4388/4885CHRM4 3944/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885RIPK1 4388/4885CHRM4 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.